BIOMAT Database Logo BIOMAT Database Logo

Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. 1987

D A Cooney, and G Ahluwalia, and H Mitsuya, and A Fridland, and M Johnson, and Z Hao, and M Dalal, and J Balzarini, and S Broder, and D G Johns

UI MeSH Term Description Entries
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D011683 Purine-Nucleoside Phosphorylase An enzyme that catalyzes the reaction between a purine nucleoside and orthophosphate to form a free purine plus ribose-5-phosphate. EC 2.4.2.1. Inosine Phosphorylase,Nicotinamide Riboside Phosphorylase,Purine Nucleoside Phosphorylases,Nucleoside Phosphorylases, Purine,Phosphorylase, Inosine,Phosphorylase, Nicotinamide Riboside,Phosphorylase, Purine-Nucleoside,Phosphorylases, Purine Nucleoside,Purine Nucleoside Phosphorylase,Riboside Phosphorylase, Nicotinamide
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003839 Deoxyadenosines Adenosine molecules which can be substituted in any position, but are lacking one hydroxyl group in the ribose part of the molecule. Adenine Deoxyribonucleosides,Adenylyldeoxyribonucleosides,Deoxyadenosine Derivatives,Deoxyribonucleosides, Adenine,Derivatives, Deoxyadenosine
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000243 Adenosine Deaminase An enzyme that catalyzes the hydrolysis of ADENOSINE to INOSINE with the elimination of AMMONIA. Adenosine Aminohydrolase,Aminohydrolase, Adenosine,Deaminase, Adenosine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D016048 Dideoxyadenosine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite. 2',3'-Dideoxyadenosine,ddA (Antiviral),2',3' Dideoxyadenosine

Related Publications

D A Cooney, and G Ahluwalia, and H Mitsuya, and A Fridland, and M Johnson, and Z Hao, and M Dalal, and J Balzarini, and S Broder, and D G Johns
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.
July 1986, Biochemical pharmacology,
D A Cooney, and G Ahluwalia, and H Mitsuya, and A Fridland, and M Johnson, and Z Hao, and M Dalal, and J Balzarini, and S Broder, and D G Johns
Initial studies on the cellular pharmacology of 3'-deoxythymidin-2'-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus.
December 1988, Biochemical pharmacology,
D A Cooney, and G Ahluwalia, and H Mitsuya, and A Fridland, and M Johnson, and Z Hao, and M Dalal, and J Balzarini, and S Broder, and D G Johns
AN ALTERNATIVE SYNTHESIS OF 2', 3'-DIDEOXYADENOSINE.
August 1965, The Journal of organic chemistry,
D A Cooney, and G Ahluwalia, and H Mitsuya, and A Fridland, and M Johnson, and Z Hao, and M Dalal, and J Balzarini, and S Broder, and D G Johns
Enzymatic properties of the unnatural beta-L-enantiomers of 2',3'-dideoxyadenosine and 2',3'-didehydro-2',3'-dideoxyadenosine.
November 1997, Journal of medicinal chemistry,
D A Cooney, and G Ahluwalia, and H Mitsuya, and A Fridland, and M Johnson, and Z Hao, and M Dalal, and J Balzarini, and S Broder, and D G Johns
Synthesis of the 2-chloro analogues of 3'-deoxyadenosine, 2',3'-dideoxyadenosine, and 2',3'-didehydro-2',3'-dideoxyadenosine as potential antiviral agents.
May 1989, Journal of medicinal chemistry,
D A Cooney, and G Ahluwalia, and H Mitsuya, and A Fridland, and M Johnson, and Z Hao, and M Dalal, and J Balzarini, and S Broder, and D G Johns
Purine nucleosides. XII. The preparation of 2',3'-dideoxyadenosine, 2',5'-dideoxyadenosine, and 2',3',5'-trideoxyadenosine from 2'-deoxyadenosine.
January 1966, Biochemistry,
D A Cooney, and G Ahluwalia, and H Mitsuya, and A Fridland, and M Johnson, and Z Hao, and M Dalal, and J Balzarini, and S Broder, and D G Johns
The 2',3'-dideoxyriboside of 2,6-diaminopurine and its 2',3'-didehydro derivative inhibit the deamination of 2',3'-dideoxyadenosine, an inhibitor of human immunodeficiency virus (HIV) replication.
May 1987, Biochemical and biophysical research communications,
D A Cooney, and G Ahluwalia, and H Mitsuya, and A Fridland, and M Johnson, and Z Hao, and M Dalal, and J Balzarini, and S Broder, and D G Johns
Pharmacokinetics of 2',3'-dideoxyadenosine in dogs.
May 1991, Investigational new drugs,
D A Cooney, and G Ahluwalia, and H Mitsuya, and A Fridland, and M Johnson, and Z Hao, and M Dalal, and J Balzarini, and S Broder, and D G Johns
Pharmacological inhibition of infectivity of HTLV-III in vitro.
September 1985, Cancer research,
D A Cooney, and G Ahluwalia, and H Mitsuya, and A Fridland, and M Johnson, and Z Hao, and M Dalal, and J Balzarini, and S Broder, and D G Johns
Disposition of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in mice.
July 1989, Investigational new drugs,
Copied contents to your clipboard!